Nanotechnology-based drug delivery for central nervous system disorders

Nguyen, Thuy Trang; Nguyen, Thi Thuy Dung; Vo, Tuong Kha; Tran, Nguyen‐Minh‐An; Nguyen, Minh Kim; Vo, Toi Van; Giau, Vo Van

doi:10.1016/j.biopha.2021.112117

Cited by 99 publications

(46 citation statements)

References 141 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Reduced in IBD (293,297) Increased in IBS (248,302) Increased in UC (252) and in CD (293) Reduced in CD (252,298) Increased in Parkinson's disease (259) Increased in Alzheimer's disease (300) Decreased in autism spectrum disorder (301) Decreased in bipolar disorder (258) Increases 5-HT levels (232) Correlated with levels of serotonin (303) Veillonellaceae Increased in IBS (304,305) Increased in IBD (305,306) Increased in UC and CD (252) Decreased in autism spectrum disorder (256) Correlated with increased levels of serotonin (307) Lactobacillaceae Increased in IBS (248) Increased in IBD (297) Decreased in IBD (Lactobacillus) (250) Increased in CD and reduced in UC (252) Increased in Parkinson's disease (253,255,308) Decreased in Alzheimer's disease (251) Increased in Alzheimer's disease (300) Increased in autism spectrum disorder (257) Decreases TPH1, 5-THR 3 and 5-HTR 4 expression; and increases SERT expression…”

Section: Ruminococcaceaementioning

confidence: 99%

“…Decreased in Parkinson's disease (259) Increased in autism spectrum disorder (256,257) Correlated with levels of serotonin (303) Prevotellaceae Decreased in IBS (248) Increased in IBS (304) Increased in IBD (326) Increased in UC and CD (252) Decreased in Parkinson's disease (254,327) Decreased in autism spectrum disorder (256,321) Proteobacteria Enterobacteriaceae Increased in IBS (302) Increased in IBD (292,306) Increased in UC and CD (252) Increased in Parkinson's disease (328) Increased in Alzheimer's disease (300) Increased in autism spectrum disorder (257) Decreases 5-HT and SERT protein (329) Increase 5-HT bioavailability (330) Increases EC cells (331) Serotonin-producing bacterial strains (Escherichia coli K-12) insufficient, and novel studies have indicated that more treatments addressing innate immunity should be carried out. In this context, several studies have indicated that TLR (353) and NLR (354) modulation may help in the treatment of these chronic pathologies.…”

Section: Ruminococcaceaementioning

confidence: 99%

See 1 more Smart Citation

Crosstalk Between Intestinal Serotonergic System and Pattern Recognition Receptors on the Microbiota–Gut–Brain Axis

et al. 2021

View full text Add to dashboard Cite

Disruption of the microbiota–gut–brain axis results in a wide range of pathologies that are affected, from the brain to the intestine. Gut hormones released by enteroendocrine cells to the gastrointestinal (GI) tract are important signaling molecules within this axis. In the search for the language that allows microbiota to communicate with the gut and the brain, serotonin seems to be the most important mediator. In recent years, serotonin has emerged as a key neurotransmitter in the gut–brain axis because it largely contributes to both GI and brain physiology. In addition, intestinal microbiota are crucial in serotonin signaling, which gives more relevance to the role of the serotonin as an important mediator in microbiota–host interactions. Despite the numerous investigations focused on the gut–brain axis and the pathologies associated, little is known regarding how serotonin can mediate in the microbiota–gut–brain axis. In this review, we will mainly discuss serotonergic system modulation by microbiota as a pathway of communication between intestinal microbes and the body on the microbiota–gut–brain axis, and we explore novel therapeutic approaches for GI diseases and mental disorders.

show abstract

Section: Ruminococcaceaementioning

confidence: 99%

Section: Ruminococcaceaementioning

confidence: 99%

Crosstalk Between Intestinal Serotonergic System and Pattern Recognition Receptors on the Microbiota–Gut–Brain Axis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Frontotemporal dementia is a prevalent type of dementia that affects people under 65 [127]. A nanotechnology-based drug delivery platform offers prospective therapeutic methods for treating several common neurological illnesses, including frontotemporal de-mentia, among innovative strategies to overcome these restrictions and successfully deliver medications to the CNS [128].…”

Section: Frontotemporal Dementiamentioning

confidence: 99%

Applications of Various Types of Nanomaterials for the Treatment of Neurological Disorders

et al. 2022

View full text Add to dashboard Cite

Neurological disorders (NDs) are recognized as one of the major health concerns globally. According to the World Health Organization (WHO), neurological disorders are one of the main causes of mortality worldwide. Neurological disorders include Alzheimer’s disease, Parkinson′s disease, Huntington′s disease, Amyotrophic lateral sclerosis, Frontotemporal dementia, Prion disease, Brain tumor, Spinal cord injury, and Stroke. These diseases are considered incurable diseases because no specific therapies are available to cross the blood-brain barrier (BBB) and reach the brain in a significant amount for the pharmacological effect in the brain. There is a need for the development of strategies that can improve the efficacy of drugs and circumvent BBB. One of the promising approaches is the use of different types of nano-scale materials. These nano-based drugs have the ability to increase the therapeutic effect, reduce toxicity, exhibit good stability, targeted delivery, and drug loading capacity. Different types and shapes of nanomaterials have been widely used for the treatment of neurological disorders, including quantum dots, dendrimers, metallic nanoparticles, polymeric nanoparticles, carbon nanotubes, liposomes, and micelles. These nanoparticles have unique characteristics, including sensitivity, selectivity, and the ability to cross the BBB when used in nano-sized particles, and are widely used for imaging studies and treatment of NDs. In this review, we briefly summarized the recent literature on the use of various nanomaterials and their mechanism of action for the treatment of various types of neurological disorders.

show abstract

“…Ideal NPs should have appropriate physiochemical properties, good biocompatibility, and effective production magnification [204] . NPs are small, nanoscale carrier structures that can be designed or modified to encapsulate or attach to molecules, peptides, proteins, antibodies, and nucleic acids [205] . There is currently a variety of NPs being explored for CNS drug delivery, including gold, hydrogels, liposomes, etc.…”

Section: Bbb Crossingmentioning

confidence: 99%

Tau-targeting therapy in Alzheimer’s disease: critical advances and future opportunities

Guo¹,

Li²,

Zeng³

et al. 2022

Ageing Neur Dis

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by two pathological hallmark lesions: extracellular plaques composed of β-amyloid (Aβ) peptide and intracellular neurofibrillary tangles made up of highly phosphorylated tau protein. Over the past two decades, most disease-modifying therapies against AD have been developed mainly on the basis of the amyloid cascade hypothesis with a focus on Aβ. However, these agents yielded only limited benefits against disease progression, which prompts us to revitalize the long-neglected tau hypothesis. Tau protein is a microtubule-associated protein, which can stabilize microtubules, regulate microtubule assembly, and affect the morphology and growth of neuronal axons. Much more importantly, the degree of tau pathology is more closely related to cognitive decline in AD patients than that of Aβ pathology. Therefore, tau-targeting therapy seems to be a promising approach to combat AD. This review describes the research progress of tau-targeting therapy in AD, with an emphasis on immunotherapy. The current challenges and future perspectives in this field are also discussed.

show abstract

Nanotechnology-based drug delivery for central nervous system disorders

Cited by 99 publications

References 141 publications

Crosstalk Between Intestinal Serotonergic System and Pattern Recognition Receptors on the Microbiota–Gut–Brain Axis

Crosstalk Between Intestinal Serotonergic System and Pattern Recognition Receptors on the Microbiota–Gut–Brain Axis

Applications of Various Types of Nanomaterials for the Treatment of Neurological Disorders

Tau-targeting therapy in Alzheimer’s disease: critical advances and future opportunities

Contact Info

Product

Resources

About